Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Detalles Bibliográficos
Autores principales: Fraunhoffer, Nicolas A., Abuelafia, Analía Meilerman, Dusetti, Nelson, Iovanna, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558692/
https://www.ncbi.nlm.nih.gov/pubmed/35848462
http://dx.doi.org/10.1002/cac2.12335
_version_ 1784807497461137408
author Fraunhoffer, Nicolas A.
Abuelafia, Analía Meilerman
Dusetti, Nelson
Iovanna, Juan
author_facet Fraunhoffer, Nicolas A.
Abuelafia, Analía Meilerman
Dusetti, Nelson
Iovanna, Juan
author_sort Fraunhoffer, Nicolas A.
collection PubMed
description
format Online
Article
Text
id pubmed-9558692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95586922022-10-16 Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool Fraunhoffer, Nicolas A. Abuelafia, Analía Meilerman Dusetti, Nelson Iovanna, Juan Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2022-07-18 /pmc/articles/PMC9558692/ /pubmed/35848462 http://dx.doi.org/10.1002/cac2.12335 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Fraunhoffer, Nicolas A.
Abuelafia, Analía Meilerman
Dusetti, Nelson
Iovanna, Juan
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
title Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
title_full Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
title_fullStr Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
title_full_unstemmed Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
title_short Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
title_sort limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558692/
https://www.ncbi.nlm.nih.gov/pubmed/35848462
http://dx.doi.org/10.1002/cac2.12335
work_keys_str_mv AT fraunhoffernicolasa limitationandchallengesinusingpancreaticcancerderivedorganoidsasapreclinicaltool
AT abuelafiaanaliameilerman limitationandchallengesinusingpancreaticcancerderivedorganoidsasapreclinicaltool
AT dusettinelson limitationandchallengesinusingpancreaticcancerderivedorganoidsasapreclinicaltool
AT iovannajuan limitationandchallengesinusingpancreaticcancerderivedorganoidsasapreclinicaltool

Ejemplares similares